Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director | August 01, 2026 | August 04, 2026 |
| Kodiak Sciences Inc.KOD · Entity 4388 | Director | June 30, 2026 | July 02, 2026 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | June 17, 2026 | June 18, 2026 |
| Neurogene Inc.AQXP · Entity 5160 | Director | March 23, 2017 | March 27, 2017 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date August 01, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 22,359 |
Reported balance
After 2026-08-01 transaction · row 1
1 source rowRow 1 · 2026-08-01 · Exercise / conversion · Acquired 403 · Balance 22,359 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 403 |
Reported balance
After 2026-08-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-01 · Grant · Acquired 403 · Balance 403 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-01 · Exercise / conversion · Disposed 403 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs.
Kodiak Sciences Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.96 · Expires 2036-06-29 | Direct | 17,731 |
Reported balance
After 2026-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 17,731 · Balance 17,731 F1: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.
MADRIGAL PHARMACEUTICALS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,469 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 454 · Balance 22,469 F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $499.86 · Expires 2036-06-17 | Direct | 766 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 766 · Balance 766 F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
Neurogene Inc.
Report date March 23, 2017 · Filed March 27, 2017
This filing explicitly reported no securities owned.
Protara Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14 | Direct | 31,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONSTELLATION PHARMACEUTICALS INC
Report date July 15, 2021 · Filed July 19, 2021
Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.57 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.29 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-15 · Disposition to issuer · Disposed 26,342 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2017 Filed Aug 23, 2017 20:03 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 2,944 | $16.12 | $47,457.28 |
DisclosureSEC source: 0001179110-17-011766 · edgar.xml · nonDerivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,973 Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:03 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 389 | $16.10 | $6,262.90 |
DisclosureSEC source: 0001179110-17-011766 · edgar.xml · nonDerivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,029 Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:03 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 90 | $15.99 | $1,439.10 |
DisclosureSEC source: 0001179110-17-011766 · edgar.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,640 Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 20:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 590 | $16.09 | $9,493.10 |
DisclosureSEC source: 0001179110-17-011725 · edgar.xml · nonDerivative · entry 12 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,550 Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 20:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 440 | $16.07 | $7,070.80 |
DisclosureSEC source: 0001179110-17-011725 · edgar.xml · nonDerivative · entry 11 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,960 Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 20:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 210 | $16.04 | $3,368.40 |
DisclosureSEC source: 0001179110-17-011725 · edgar.xml · nonDerivative · entry 10 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,520 Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 20:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 200 | $16.02 | $3,204.00 |
DisclosureSEC source: 0001179110-17-011725 · edgar.xml · nonDerivative · entry 9 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,310 Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 20:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 200 | $15.93 | $3,186.00 |
DisclosureSEC source: 0001179110-17-011725 · edgar.xml · nonDerivative · entry 8 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,110 Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 20:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 10 | $15.90 | $159.00 |
DisclosureSEC source: 0001179110-17-011725 · edgar.xml · nonDerivative · entry 7 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,910 Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 20:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 400 | $15.80 | $6,320.00 |
DisclosureSEC source: 0001179110-17-011725 · edgar.xml · nonDerivative · entry 6 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 20:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 200 | $15.79 | $3,158.00 |
DisclosureSEC source: 0001179110-17-011725 · edgar.xml · nonDerivative · entry 5 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 20:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 200 | $15.77 | $3,154.00 |
DisclosureSEC source: 0001179110-17-011725 · edgar.xml · nonDerivative · entry 4 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 20:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 100 | $15.72 | $1,572.00 |
DisclosureSEC source: 0001179110-17-011725 · edgar.xml · nonDerivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 20:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 100 | $15.70 | $1,570.00 |
DisclosureSEC source: 0001179110-17-011725 · edgar.xml · nonDerivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 20:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 900 | $15.67 | $14,103.00 |
DisclosureSEC source: 0001179110-17-011725 · edgar.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 22:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $16.46 | $0.00 |
DisclosureSEC source: 0001179110-17-009845 · edgar.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-29 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the date of grant, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| August 11, 2016 Filed Nov 21, 2016 21:40 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001179110-16-031900 · edgar.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-08-11 F1 · derivative.exercise_date: Fifty percent (50%) of the option vests on August 11, 2017 and thereafter it vests at a rate of twelve and one-half percent (12.5%) per quarter for four (4) successive quarters. The filing is late due to an administrative oversight. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.